PCN136 Cost-Effectiveness Analysis of Dacomitinib Versus Gefitinib for the First-line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR)-Activating Mutations in Portugal
| Autor: | Silva Miguel, L., Paquete, A.T., Alarcão, J., Guerreiro, R., Inês, M., Borges, M. |
|---|---|
| Zdroj: | In Value in Health December 2020 23 Supplement 2:S447-S447 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect